SVAS Biosana S.p.A (SVS) Fair Value & Analysis

Healthcare · IT · Market cap €49.0M

Analysis

SVAS Biosana S.p.A (SVS) currently trades at €9.04, while our model-based Fair Value estimate is €28.38 — implying the stock looks roughly 213.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

SVAS Biosana S.p.A. engages in the production and marketing of medical devices worldwide. The company offers incontinence aids, traditional dressings, and personal care products for use in incontinence devices, dressings, and personal care product applications. It also offers operating packs, medical devices, infusion and aspiration, linen, advanced dressings, and lubricating gels that are used in haemodynamic, heart surgery, anaesthesia, and critical care applications. In addition, the company provides specialist medical devices for use in oncology, intensive care, chronic illnesses, and surgeries; and medical devices for use in radiology and diagnostic imaging, orthopaedics, cardiology, heart surgery, and critical care applications. SVAS Biosana S.p.A. was founded in 1972 and is based in Somma Vesuviana, Italy.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.